MedAlliance announced today that its novel sirolimus-eluting balloon received conditional FDA investigational device exemption (IDE).
Geneva, Switzerland-based MedAlliance can now initiate its pivotal clinical trial for the treatment of coronary de novo lesions.
Get the full story at our sister site, Drug Delivery Business News.